COVID-19 vaccine Janssen - EMA: possible link to very rare cases of unusual blood clots with low blood platelets - Overall benefit-risk remains positive


EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen.
PRAC has also concluded that these events should be listed as very rare side effects of the vaccine.

In reaching the conclusion, the Committee took into consideration all currently available evidence including eight reports from the United States of serious cases of unusual blood clots associated with low levels of blood platelets, one of which had a fatal outcome.
As of 13 April 2021, over 7 million people had received Janssen’s vaccine in the United States.

All cases occurred in people under 60 years of age within three weeks after vaccination, the majority in women.
Based on the currently available evidence, specific risk factors have not been confirmed.

PRAC noted that the blood clots occurred mostly at unusual sites such as in veins in the brain ( cerebral venous sinus thrombosis, CVST ) and the abdomen ( splanchnic vein thrombosis ) and in arteries, together with low levels of blood platelets and sometimes bleeding.
The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria.

Healthcare professionals and people who will receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination.

COVID-19 is associated with a risk of hospitalisation and death. The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects.

One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin called heparin induced thrombocytopenia, HIT.

PRAC has emphasised the importance of prompt specialist medical treatment. By recognising the signs of bloods clots and low blood platelets and treating them early, healthcare professionals can help those affected in their recovery and avoid complications.
Thrombosis in combination with thrombocytopenia requires specialised clinical management.
Healthcare professionals should consult applicable guidance and/or consult specialists ( e.g., haematologists, specialists in coagulation ) to diagnose and treat this condition.

A similar signal evaluation was recently finalised for another COVID-19 vaccine, Vaxzevria ( previously COVID-19 Vaccine AstraZeneca ).

COVID-19 vaccine Janssen is a vaccine for preventing coronavirus disease 2019 ( COVID-19 ) in people aged 18 years and older.
COVID-19 is caused by SARS-CoV-2 virus.
COVID-19 vaccine Janssen is made up of another virus ( adenovirus family ) that has been modified to contain the gene for making a protein from SARS-CoV-2.
COVID-19 vaccine Janssen does not contain the virus itself and cannot cause COVID-19.

The most common side effects with COVID-19 vaccine Janssen are usually mild or moderate and improve within a few days after vaccination.

Information for healthcare professionals

EMA has reviewed eight cases of thrombosis in combination with thrombocytopenia in people who received Janssen’s COVID-19 vaccine in the United States.

These very rare types of thrombosis ( with thrombocytopenia ) included venous thrombosis mostly in unusual sites such as cerebral venous sinus thrombosis and splanchnic vein thrombosis, as well as arterial thrombosis, and fatal outcome in one case. All cases occurred in people below 60 years of age, and most were in women, within three weeks of the person being vaccinated.

The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria.

As for the mechanism, it is thought that the vaccine may trigger an immune response leading to a Heparin-induced-thrombocytopenia like disorder. At this time, the pathophysiological mechanism has not been established, and it is currently not possible to identify specific risk factors.

Healthcare professionals should be alert to the signs and symptoms of thromboembolism and thrombocytopenia so that they can promptly treat people affected in line with available guidelines.

Thrombosis in combination with thrombocytopenia requires specialised clinical management. Healthcare professionals should consult applicable guidance and/or consult specialists ( e.g., haematologists, specialists in coagulation ) to diagnose and treat this condition.

Healthcare professionals should tell people receiving the vaccine that they must seek medical attention if they develop: symptoms of blood clots such as shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms such as severe and persistent headaches and blurred vision, petechiae beyond the site of vaccination after a few days.

The benefits of the vaccine continue to outweigh the risks for people who receive it. The vaccine is effective at preventing COVID-19 and reducing hospitalisations and deaths. ( Xagena )

Source: EMA, 2021

XagenaMedicine_2021



Indietro

Altri articoli

Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at...


The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...


The FDA ( U.S. Food and Drug Administration ) has approved Opdivo ( Nivolumab ) 240 mg injection for intravenous...


The European Commission ( EC ) has approved Bavencio ( Avelumab ) as monotherapy for the first-line maintenance treatment of...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus...


The Food and Drug Administration ( FDA ) has approved Xalkori ( Crizotinib ) for pediatric patients 1 year of...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...


The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric...


The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...